A clinical perspective for the management of invasive fungal infections: Focus on IDSA guidelines

Pharmacotherapy

Volumn 21, Issue 8 SUPPL. 2, 2001, Pages

  Kontoyiannis, D P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; RAVUCONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

ASPERGILLOSIS; BLASTOMYCOSIS; CANDIDIASIS; COCCIDIOIDOMYCOSIS; CRYPTOCOCCOSIS; HISTOPLASMOSIS; MYCOSIS; PRACTICE GUIDELINE; REVIEW; SPOROTRICHOSIS;

EID: 0034903876     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.21.12.175s.34506     Document Type: Review

References (139)

1. Systemic mycoses in the 21st century
2. Amphotericin B: 30 years of experience
3. Clinical pharmacology of systemic antifungal agents: A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development
4. Current and emerging azole antifungal agents
5. Antifungal agents: Chemotherapeutic targets and immunologic strategies
6. Introduction to antifungal drugs
7. General guidelines for the evaluation of new antifungal drugs for the treatment of systemic fungal infections
8. International conference for the development of a consensus on the management and prevention of severe candidal infections
9. Practice guidelines for the treatment of fungal infections
10. Practice guidelines for the treatment of candidiasis
11. Practice guidelines for the treatment of coccidioidomycosis
12. Practice guidelines for the management of patients with blastomycosis
13. Practice guidelines for the management of patients with sporotrichosis
14. Practice guidelines for the management of patients with histoplasmosis
15. Practice guidelines for diseases caused by Aspergillus
16. Practice guidelines for the management of cryptococcal disease
17. Hematogenous and major organ candidiasis
18. Nosocomial candidemia: Risk factors and attributable mortality
19. Nosocomial candidiasis: Emerging species, reservoirs and modes of transmission
20. Hospital-acquired candidemia: The attributable mortality and excess length of stay
21. Candidemia in a tertiary care hospital: Epidemiology, risk-factors, and predictors of mortality
22. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy
23. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole and Candida infections
24. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia
25. Management of candidemia
26. Therapeutic approaches in patients with candidemia
27. Multicenter randomized trial of fluconazole versus amphotericin B for the treatment of candidemia in non-neutropenic patients
28. Fluconazole versus amphotericin B for the treatment of candidemia in adults: A meta-analysis
29. Can we agree on the treatment of candidiasis?
30. Problems and controversies in the management of hematogenous candidiasis
31. Is antifungal susceptibility testing useful in guiding fluconazole therapy?
32. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of non-neutropenic patients with candidemia
33. When should Candida isolates be tested for susceptibility to azole antifungal agents?
34. Catheters and candidemia
35. Candiduria: A randomized, double-blind study of treatment with fluconazole and placebo
36. Treatment of funguria
37. Predictors of adverse outcome in cancer patients with candidemia
38. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: Frequency, characteristics, and evaluation of factors influencing outcome
39. Etiologic organisms as independent predictors of death and morbidity associated with bloodstream infections
40. Nosocomial fungemia in a large community teaching hospital
41. A pilot study of the management of uncomplicated candidemia with a standardized protocol of amphotericin B
42. Hepatosplenic candidiasis: A manifestation of chronic disseminated candidiasis
43. Incidence and risk of developing fungal prosthetic valve endocarditis after nosocomial candidemia
44. Notes: Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North American and Latin America, 1997-1998
45. Candida krusei fungemia: An escalating serious infection in immuno-compromised patients
46. Candida glabrata: Review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans
47. Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches
48. Importance of Candida species other than C. albicans as pathogens in oncology patients
49. The epidemiology of hematogenous candidiasis caused by different Candida species
50. Management of invasive candidal infections: Results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature
51. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: A matched cohort study
52. Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever-preliminary observation from a pilot, exploratory study
53. A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients
54. Fluconazole versus amphotericin B as empirical therapy for unexplained fever in granulocytopenic cancer patients: A pragmatic, multicenter, prospective and randomized clinical trial
55. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer
56. Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders
57. Risk factors for Candida tropicalis fungemia in patients with cancer
58. Risk factors and predictors of outcome in cancer patients with breakthrough candidemia
59. Management of infections caused by Candida glabrata
60. Azole resistance in Candida
61. Antifungal susceptibility testing: Technical advances and potential clinical applications
62. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole
63. Notes: Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: Results from a multicenter prospective study of candidemia
64. Importance of Candida species other than Candida albicans as opportunistic pathogens
65. Emergence of a new opportunistic pathogen, Candida lusitaniae
66. Vascular catheter-associated fungemia in patients with cancer: Analysis of 155 episodes
67. Outcome of treatment of candidemia in children whose central catheters were removed or retained
68. Intravascular catheter exchange and duration of candidemia
69. The role of the gastrointestinal tract in hematogenous candidiasis: From the laboratory to the bedside
70. Biofilm and central venous catheter-related infections. Evidence of universal colonization and low risk of hematogenous seeding
71. Diagnosis of catheter-related bloodstream infection (CRBSI): Differential time to positivity (DTP) for short-term and tong-term central venous catheters (CVC)
72. Laboratory diagnosis of candidiasis
73. New perspectives in the diagnosis of systemic fungal infections
74. Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients
75. Study group of fungal infection in the ICU
76. Candida sepsis in surgical patients
77. Prevention of candidal infection in immunocompromised patients: What for whom?
78. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
79. Estimating the true cost of amphotericin B
80. Choosing amphotericin B formulations-between a rock and a hard place
81. In vivo pharmacodynamic of amphotericin B (AmB) against C. albicans
82. Notes: Fluconazole treatment of candidal infections cause by non-albicans Candida species
83. Use of amphotericin B with azole antifungal drugs: What are we doing?
84. Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model
85. Use of macrophage colony-stimulating factor in the treatment of fungal infections
86. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: A pilot study
87. The potential role of cytokine therapy for fungal infections in patients with cancer: Is recovery from neutropenia all that is needed?
88. Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients
89. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients
90. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: Long-term follow-up of a randomized, placebo-controlled trial
91. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis
92. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital
93. Fungal infections in cancer patients
94. Epidemiology of visceral mycoses: Analysis of data in annual of the pathological autopsy cases in Japan
95. Aspergillus fumigatus and aspergillosis
96. Aspergillosis
97. Antifungal and surgical treatment of invasive aspergillosis: Review of 2,121 published cases
98. Therapeutic outcome in invasive aspergillosis
99. Treatment failure in invasive aspergillosis due to poor tissue penetration by antifungal agents
100. Invasive aspergillosis: Disease spectrum, treatment practices, and outcomes
101. Diversity of literature on mortality associated with invasive aspergillosis
102. Treatment strategies for Aspergillus infections
103. Lipid formulations of amphotericin B
104. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases
105. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis
106. Pharmaco-economic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients
107. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia
108. High-dose liposomal in patients infected with aspergillosis and other filamentous fungi
109. Progressive disseminated aspergillosis in a bone marrow transplant recipient: Response with high dose of liposomal amphotericin B
110. An EORTC international muticenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis
111. Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID mycoses study group criteria
112. Acquired resistance of Aspergillus fumigatus to itraconazole
113. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis
114. Early diagnosis of invasive aspergillosis
115. Evaluation of PCR for detection of DNA specific for Aspergillus species in sera of patients with various forms of pulmonary aspergillosis
116. Early detection of Aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening
117. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery
118. Management of invasive pulmonary aspergillosis in hematology patients: A review of 87 consecutive cases at a single institution
119. An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (SCH 56592) in the treatment of invasive fungal infections (IFI) refractory (R) to or intolerant (I) to standard therapy (ST)
120. The efficacy and tolerability of UK-109,496 (voriconazole), in the treatment of invasive aspergillosis
121. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice
122. Multicenter, non-comparative study to evaluate safety and efficacy of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory (R) or intolerant (I) to amphotericin B (AmB), AmB lipid formulations (lipid AmB), or azoles
123. Drug interaction in vitro between a polyene (AmBisome; AmBi) and an echinocandin (FK463) vs. Aspergillus species
124. In vitro interaction of antifungals against itraconazole-susceptible and resistant Aspergillus fumigatus isolates
125. The past, present and future of antimycotic combination therapy
126. Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: An E-test-based strategy
127. Problems of antifungal in vitro testing in Aspergillus fumigatus
128. In vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis
129. Lack of correlation in in vitro amphotericin B susceptibility testing with outcome in a model of Aspergillus infection
130. Evaluation of antifungal susceptibility testing for filamentous fungi assayed by broth microdilution and Etest
131. Trends in immunotherapy of fungal infections
132. Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans
133. Cryptococcosis in the 1990s in a tertiary care cancer center
134. Coccidioidomycosis
135. Histoplasmosis
136. Comparison of oral fluconazole and itraconazole for progressive, non-meningeal coccidioidomycosis
137. Antifungal drug resistance in pathogenic fungi